METHOD FOR DETECTION OF EPITHELIAL DYSPLASIA OF GASTRIC MUCOSA IN ATROPHIC CHANGES Russian patent published in 2016 - IPC G01N33/535 

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Method is characterised by determining in patient's blood serum concentrations of pepsinogens I and II, calculating concentration pepsinogen I to concentration of pepsinogen II. If this ratio is equal to or below lower limit of normal, concentration of interferonγ (IFNγ) in supernatant of blood sample of given patient after its incubation with a cancer-embryonic antigen (CEA) and without it, an index of effect of (IE) CEA for production of IFNγ (CEA IE IFNγ) blood cells by formula: CEA IE IFNγ= A/B, where A is concentration of IFNγ in supernatant of blood sample after its incubation with CEA, B is concentration of IFNγ in supernatant of blood sample without its incubation with CEA, and if CEA IE IFNγ, is equal to or lower than 1.2, presence of epithelial dysplasia of gastric mucosa 2 or 3 degree, and if CEA IE IFNγ, higher than 1.2, absence of epithelial dysplasia of gastric mucosa in said patient or presence therein of dysplasia 1 degree. When used for immune-enzyme assay of sets of reagents “Pepsinogen 1-IFA-BEST” and “Pepsinogen 2-IFA-BEST” produced by JSC “Vector-Best” lower limit of normal concentrations of pepsinogen I to concentration of pepsinogen II is taken as equal to three. Method allows detecting dysplasia (cellular atypism) gastric mucosa epithelium 2 or 3 degree in patients which have not been detected gastric mucosa atrophy, that is, disclosed method makes it possible to generate a risk group of patients at development of gastric oncopathology and its prevention.

EFFECT: method is highly sensitive, highly specific, low-invasive.

2 cl